Alliances
Help Us Shape the Future of Medicines
To realize our mission of translating a great scientific idea into a real, transformative medicine for patients, we rely on external partners who bring expertise, investment, and scaling capacity to our pipeline. It’s these critical partnerships that ensure there is a path to patients beyond the walls of Stanford.
“The IMA continues to seek high-quality partners in our mission as an accelerator, and we are excited about engaging diverse partners in helping us scale Stanford-grown solutions.”
Chaitan Khosla
Director
Featured Alliances
Learn more about some of the alliances that are critical to our success.
OmniAb
OmniAb® provides partners access to the most diverse antibody repertoires and cutting-edge screening technologies to enable discovery of next-generation therapeutics.
Celltaxis
Celltaxis and the IMA are collaborating to test a new medicine for lymphedema.
Vergent Bioscience
This collaboration enables the clinical testing of imaging agents to improve surgical outcomes.
The Invus Group
The investment firm is supporting the development of treatments for glioblastoma.
Alloy Therapeutics
Alloy’s immunocompetent transgenic mice enable best-in-class in vivo human antibody discovery.
Simcere Pharmaceutical
This collaboration with Simcere Pharmaceutical enables the lead identification of a novel therapeutic for Parkinson’s disease.
Twist Bioscience
Twist’s “Library of Libraries” and other services accelerate the discovery of antibody and other biologics-focused therapies.
Porter Alliance for Innovative Medicines
This collaboration with Deerfield Management Company supports projects with the potential to cure life-altering diseases.
Featured Projects
Fluoxetine analog for glioblastoma therapy
Based on in vitro, animal and human evidence, the Mischel laboratory has established that the SSRI drug fluoxetine is an effective therapy for glioblastoma. The goal of this project is to introduce a superior fluoxetine analog into clinical trials for this highly lethal form of cancer. For more information about this project, see the team’s […]
Acebilustat for lymphedema
Acebilustat (CTX-4430) is a potent inhibitor of leukotriene A4 hydrolase, the rate-limiting enzyme in the biosynthesis of the chemoattractant and proinflammatory agent leukotriene B4. Prior human studies have established the safety of this experimental medicine up to a 100 mg daily dose and have demonstrated reduction in sputum white blood cell counts in cystic fibrosis […]
Come on Board
Our partners are critical to our success.
Looking to start an alliance with us? Have questions?
Contact Alliance Director Paul Humphries.
Related Articles
Stanford University and The Invus Group collaborate to develop glioblastoma drugs
Deerfield, Stanford University create Porter Alliance for Innovative Medicines
Stanford University and The Invus Group collaborate to develop glioblastoma drugs